Table 2 Transplant-related events... | American Society of Hematology

Table 2

Transplant-related events univariate analysis

Outcome	OS	GPFS	NRM	Relapse incidence	Grade III-IV aGVHD	NIH grade 2-3 cGVHD
Patient age
<60 years	69.2 (54.2-80.2)	42.3 (28.3-55.6)	16.5 (7.6-28.2)	27.1 (15.3-40.3)	14.3 (6.2-25.6)	16.3 (7.5-28.1)
>60 years	39.7 (19.0-54.6)	23.5 (9.4-40.4)	23.9 (10.0-41.0)	39.8 (22.1-57.0)	9.7 (2.4-23.2)	16.1 (5.7-31.4)
P	.02	.27	.57	.26	.54	.99
CMV
Donor/recipient negative	63.0 (44.6-76.7)	36.6 (21.2-52.1)	19.5 (8.4-34.0)	25.2 (12.2-40.5)	16.2 (6.5-29.9)	16.2 (6.4-29.9)
Others	52.7 (36.7-56.5)	23.3 (20.6-48.5)	18.6 (8.6-31.6)	37.8 (23.3-52.4)	9.3 (2.9-20.3)	16.3 (7.0-28.9)
P	.53	.63	.75	.10	.34	.99
Sex
Female to male 1	52.4 (29.7-70.9)	33.3 (14.9-53.1)	23.8 (8.2-43.8)	38.1 (17.6-58.5)	4.8 (0.3-20.3)	14.3 (3.3-33.1)
Other 0	59.6 (45.6-71.1)	36.2 (24.0-48.6)	17.2 (8.8-28.1)	29.8 (18.4-42.1)	15.3 (7.4-25.6)	17.0 (8.7-27.8)
P	.51	.37	.55	.57	.23	.75
Disease risk index
Low-intermediate	60.9 (47.4-71.0)	35.8 (24.1-47.7)	20.8 (11.7-31.7)	27.7 (17.1-39.4)	14.3 (7.0-24.1)	20.7 (11.6-31.6)
High-very high	45.4 (20.9-67.1)	35.3 (14.5-57.0)	11.8 (1.8-32.0)	47.1 (21.9-68.8)	5.9 (0.3-24.7)	0
P	.16	.54	.47	.08	.34	.05
Diagnosis
Lymphoid	57.7 (39.1-72.5)	34.4 (19.0-50.4)	24.0 (11.0-39.6)	27.7 (13.5-44.0)	14.7 (5.3-28.7)	20.8 (8.9-36.0)
Myeloid	57.5 (41.6-70.5)	36.1 (22.4-50.0)	15.2 (6.6-27.1)	35.4 (21.7-49.4)	10.9 (3.9-21.8)	13.0 (5.2-24.6)
P	.66	.88	.54	.35	.65	.34
Donor
MRD	70.2 (48.8-83.9)	41.3 (22.8-59.0)	7.3 (1.2-21.2)	33.4 (16.3-51.5)	7.1 (12-207)	17.9 (6.2-34.3)
UD	50.7 (36.2-63.6)	31.9 (19.7-44.8)	25.2 (14.3-37.8)	31.4 (19.1-44.5)	15.4 (71-265)	15.4 (7.1-26.6)
P	.028	.18	.04	.97	.28	.85
Conditioning regimen
MAC	53.3 (26.3-74.4)	38.9 (15.3-62.2)	34.7 (23.1-46.5)	21.0 (4.5-45.5)	13.3 (2.0-35.5)	13.3 (2.0-35.6)
RIC	58.6 (45.2-69.7)	34.5 (23.1-46.2)	15.7 (8.0-25.7)	33.3 (11.3-57.4)	12.3 (5.7-21.6)	17.0 (9.0-27.2)
P	.61	.61	.19	.39	.89	.80
ATG
Yes	57.5 (44.9-68.1)	37.6 (26.4-48.7)	19. (11.2-29.4)	27.9 (18.0-38.6)	13.7 (7.0-22.7)	13.7 (7.0-22.8)
No	57.1 (17.2-83.7)	14.3 (7.1-46.5)	14.3 (0.5-49.1)	71.4 (15.5-94.1)	0	42.9 (6.5-76.9)
P	.61	.19	.73	.01	.30	.045
GVHD prophylaxis
CSA	68.5 (46.4-83.0)	38.8 (20.4-56.9)	11.3 (2.7-26.7)	30.8 (14.1-49.2)	11.1 (2.7-26.3)	11.1 (2.6-26.5)
CSA + MMF or MTX	52.0 (37.7-64.6)	33.2 (20.9-46.1)	22.9 (12.5-35.1)	33.0 (20.5-46.1)	13.2 (5.7-23.8)	18.9 (9.6-30.5)
P	.10	.34	.16	.64	.75	.37
iNKTs
<0.11 × 10⁶/kg	54.7 (38.1-68.6)	21.7 (10.4-35.7)	20.2 (9.3-34.1)	40.6 (25.0-55.6)	15.0 (6.0-27.9)	20.0 (9.2-33.7)
>0.11 × 10⁶/kg	59.6 (41.7-73.6)	49.4 (33.1-63.8)	18.1 (7.8-31.9)	22.6 (11.1-36.6)	10.0 (3.1-21.7)	12.6 (4.5-25.2)
P	.51	.007	.97	.12	.49	.32

Outcome	OS	GPFS	NRM	Relapse incidence	Grade III-IV aGVHD	NIH grade 2-3 cGVHD
Patient age
<60 years	69.2 (54.2-80.2)	42.3 (28.3-55.6)	16.5 (7.6-28.2)	27.1 (15.3-40.3)	14.3 (6.2-25.6)	16.3 (7.5-28.1)
>60 years	39.7 (19.0-54.6)	23.5 (9.4-40.4)	23.9 (10.0-41.0)	39.8 (22.1-57.0)	9.7 (2.4-23.2)	16.1 (5.7-31.4)
P	.02	.27	.57	.26	.54	.99
CMV
Donor/recipient negative	63.0 (44.6-76.7)	36.6 (21.2-52.1)	19.5 (8.4-34.0)	25.2 (12.2-40.5)	16.2 (6.5-29.9)	16.2 (6.4-29.9)
Others	52.7 (36.7-56.5)	23.3 (20.6-48.5)	18.6 (8.6-31.6)	37.8 (23.3-52.4)	9.3 (2.9-20.3)	16.3 (7.0-28.9)
P	.53	.63	.75	.10	.34	.99
Sex
Female to male 1	52.4 (29.7-70.9)	33.3 (14.9-53.1)	23.8 (8.2-43.8)	38.1 (17.6-58.5)	4.8 (0.3-20.3)	14.3 (3.3-33.1)
Other 0	59.6 (45.6-71.1)	36.2 (24.0-48.6)	17.2 (8.8-28.1)	29.8 (18.4-42.1)	15.3 (7.4-25.6)	17.0 (8.7-27.8)
P	.51	.37	.55	.57	.23	.75
Disease risk index
Low-intermediate	60.9 (47.4-71.0)	35.8 (24.1-47.7)	20.8 (11.7-31.7)	27.7 (17.1-39.4)	14.3 (7.0-24.1)	20.7 (11.6-31.6)
High-very high	45.4 (20.9-67.1)	35.3 (14.5-57.0)	11.8 (1.8-32.0)	47.1 (21.9-68.8)	5.9 (0.3-24.7)	0
P	.16	.54	.47	.08	.34	.05
Diagnosis
Lymphoid	57.7 (39.1-72.5)	34.4 (19.0-50.4)	24.0 (11.0-39.6)	27.7 (13.5-44.0)	14.7 (5.3-28.7)	20.8 (8.9-36.0)
Myeloid	57.5 (41.6-70.5)	36.1 (22.4-50.0)	15.2 (6.6-27.1)	35.4 (21.7-49.4)	10.9 (3.9-21.8)	13.0 (5.2-24.6)
P	.66	.88	.54	.35	.65	.34
Donor
MRD	70.2 (48.8-83.9)	41.3 (22.8-59.0)	7.3 (1.2-21.2)	33.4 (16.3-51.5)	7.1 (12-207)	17.9 (6.2-34.3)
UD	50.7 (36.2-63.6)	31.9 (19.7-44.8)	25.2 (14.3-37.8)	31.4 (19.1-44.5)	15.4 (71-265)	15.4 (7.1-26.6)
P	.028	.18	.04	.97	.28	.85
Conditioning regimen
MAC	53.3 (26.3-74.4)	38.9 (15.3-62.2)	34.7 (23.1-46.5)	21.0 (4.5-45.5)	13.3 (2.0-35.5)	13.3 (2.0-35.6)
RIC	58.6 (45.2-69.7)	34.5 (23.1-46.2)	15.7 (8.0-25.7)	33.3 (11.3-57.4)	12.3 (5.7-21.6)	17.0 (9.0-27.2)
P	.61	.61	.19	.39	.89	.80
ATG
Yes	57.5 (44.9-68.1)	37.6 (26.4-48.7)	19. (11.2-29.4)	27.9 (18.0-38.6)	13.7 (7.0-22.7)	13.7 (7.0-22.8)
No	57.1 (17.2-83.7)	14.3 (7.1-46.5)	14.3 (0.5-49.1)	71.4 (15.5-94.1)	0	42.9 (6.5-76.9)
P	.61	.19	.73	.01	.30	.045
GVHD prophylaxis
CSA	68.5 (46.4-83.0)	38.8 (20.4-56.9)	11.3 (2.7-26.7)	30.8 (14.1-49.2)	11.1 (2.7-26.3)	11.1 (2.6-26.5)
CSA + MMF or MTX	52.0 (37.7-64.6)	33.2 (20.9-46.1)	22.9 (12.5-35.1)	33.0 (20.5-46.1)	13.2 (5.7-23.8)	18.9 (9.6-30.5)
P	.10	.34	.16	.64	.75	.37
iNKTs
<0.11 × 10⁶/kg	54.7 (38.1-68.6)	21.7 (10.4-35.7)	20.2 (9.3-34.1)	40.6 (25.0-55.6)	15.0 (6.0-27.9)	20.0 (9.2-33.7)
>0.11 × 10⁶/kg	59.6 (41.7-73.6)	49.4 (33.1-63.8)	18.1 (7.8-31.9)	22.6 (11.1-36.6)	10.0 (3.1-21.7)	12.6 (4.5-25.2)
P	.51	.007	.97	.12	.49	.32

Bold denotes statistically significance.

View Large

This Feature Is Available To Subscribers Only